X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AT-1501 (tegoprubart) is an experimental humanized monoclonal antibody that inhibits CD40L. It is being evaluated for the treatment of Organ Rejection.
Lead Product(s): Tegoprubart
Therapeutic Area: Immunology Product Name: AT-1501
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
AT-1501 (tegoprubart) is an investigational, humanized IgG1 anti-CD40L antibody with high affinity for the CD40 ligand, which is investigated for the treatment of prevention of rejection in kidney transplantation.
Lead Product(s): Tegoprubart
Therapeutic Area: Immunology Product Name: AT-1501
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
The Company intends to use the net proceeds to fund the clinical development of its lead asset AT-1501 (tegoprubart), an anti-CD40L antibody with high affinity for CD40 Ligand.
Lead Product(s): Tegoprubart
Therapeutic Area: Neurology Product Name: AT-1501
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $185.0 million Upfront Cash: $35.0 million
Deal Type: Private Placement May 01, 2023
Details:
AT-1501 (tegoprubart) is an investigational, humanized IgG1 anti-CD40L antibody with high affinity for the CD40 ligand. CD40L plays a pivotal role in immune system activation by mediating both antibody and cellular immune responses.
Lead Product(s): Tegoprubart
Therapeutic Area: Immunology Product Name: AT-1501
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: eGenesis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2023
Details:
Tegoprubart (AT-1501) is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L (also called CD154), a well-validated biological target with broad therapeutic potential. It was built around safety and engineered to maximize efficacy and half life.
Lead Product(s): Tegoprubart
Therapeutic Area: Nephrology Product Name: AT-1501
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
The study will evaluate the safety and efficacy of AT-1501 (tegoprubart), with the primary endpoint being change from baseline in urine protein (assessed as urine protein to creatinine ratio) after 24 weeks of therapy.
Lead Product(s): Tegoprubart
Therapeutic Area: Nephrology Product Name: AT-1501
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Tegoprubart (formerly AT-1501),an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential, for the prevention of organ rejection in patients receiving a kidney transplant.
Lead Product(s): Tegoprubart
Therapeutic Area: Immunology Product Name: AT-1501
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
AT-1501 (tegoprubart), an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential for the prevention of allograft rejection in pancreatic islet cell transplantation.
Lead Product(s): Tegoprubart
Therapeutic Area: Endocrinology Product Name: AT-1501
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
AT-1501 (Tegoprubart) is an investigational humanized monoclonal antibody that inhibits CD40 Ligand (CD40L), a membrane protein linked to increased peripheral immune responses and neuroinflammation in ALS.
Lead Product(s): Tegoprubart
Therapeutic Area: Neurology Product Name: AT-1501
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
AT-1501 (tegoprubart), is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L (also called CD154), a well-validated biological target with broad therapeutic potential.
Lead Product(s): Tegoprubart
Therapeutic Area: Nephrology Product Name: AT-1501
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
